Back to Screener

Healthcare

Getinge AB (publ)(GNGBF)

Live Price

Offline

$20.05

+0.00% today

1Y Change

-5.02%

Window

Jun 25, 2025 โ†’ Jun 24, 2026

Market Cap
$49.99B
Revenue Growth
+0.6%
EPS Growth
+37.6%
Dividend Yield
2.6%

Coverage: 250 bars ยท Jun 25, 2025 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Getinge AB (publ) (GNGBF) is a Healthcare stock with a market cap of $49.99B and listed on OTC. The stock last traded around $20.05 and down 5.0% across the available one-year price window (Jun 25, 2025 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of +37.6%, a dividend yield of 2.6%. What stands out right now is revenue +0.6%, EPS +37.6%, free cash flow -19.4% with operating margin 12.2% and ROIC 6.4%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 21.2 and price/sales 1.5. Stock Foundry combines GNGBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

GNGBF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

GNGBF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

GNGBF Max Drawdown

-18.99%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for GNGBF and SPY.

Calendar-year return history is still loading or unavailable.

Financial profile

Getinge AB (publ) (GNGBF)

Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.

FY Revenue

$27.0B

-4.4% YoY

FY Net Income

$3.0B

+19.2% YoY

Free Cash Flow

$5.6B

+152.4% YoY

Revenue Growth

+0.6%

EPS Growth

+37.6%

Gross Margin

45.7%

Net Margin

6.9%

Income statement

SEK

Annual
Metric20252024202320222021
Revenue35.0B34.8B31.8B28.3B27.0B
Gross Profit16.7B16.2B14.5B13.4B13.6B
Operating Income4.2B2.9B3.7B3.6B4.4B
EBITDA6.4B5.3B5.9B5.7B6.2B
Net Income2.3B1.6B2.4B2.5B3.0B
EPS (Diluted)โ€”โ€”โ€”โ€”โ€”

Balance sheet

SEK

Point-in-time
Metric20252024202320222021
Cash & Equivalents3.4B3.0B2.7B5.7B4.1B
Total Assets56.5B63.9B53.6B52.0B44.6B
Total Liabilities27.0B30.7B23.2B21.6B19.4B
Shareholder Equity29.4B33.0B30.2B30.0B24.7B
Total Debt10.9B10.7B8.1B5.8B4.3B
Net Debt7.5B7.8B5.3B148M230M

Cash flow positioning

Latest Full Year

Operating Cash Flow

6.6B

+94.8% YoY

Capital Expenditures

930M

+18.1% YoY

Free Cash Flow

5.6B

+152.4% YoY

Key ratios

  • Gross Margin

    45.7%

  • Operating Margin

    12.2%

  • Net Margin

    6.9%

  • ROE

    8.0%

  • Debt / Equity

    0.35x

Next Step

Turn financials into a decision

Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.